ライフサイエンスコーパス: brachytherapy

1 diotherapy; and 0.90 [95% CI, 0.85-0.95] for brachytherapy).

2 oning, and use for (131/137)Cs radiotherapy (brachytherapy).

3 nd at 12-month intervals until 2 years after brachytherapy.

4 ents randomly assigned to enucleation versus brachytherapy.

5 time of 16 months (range, 2-36 months) after brachytherapy.

6 apy, with the highest rate in high-dose-rate brachytherapy.

7 y was transpupillary thermotherapy or plaque brachytherapy.

8 le surgery frequently is required for plaque brachytherapy.

9 cation with 54 cases treated with iodine-125 brachytherapy.

10 ients were treated with palladium-103 plaque brachytherapy.

11 ated with either endoresection or iodine-125 brachytherapy.

12 es similar to those obtained with iodine-125 brachytherapy.

13 sing therapeutic alternative to conventional brachytherapy.

14 n essential component of quality outcomes in brachytherapy.

15 beam radiotherapy and 28.8 million requiring brachytherapy.

16 women in our sample, 4,671 (15.8%) received brachytherapy.

17 based on differences in surgical staging or brachytherapy.

18 apy, primary androgen deprivation therapy or brachytherapy.

19 ich 7.0 million also required treatment with brachytherapy.

20 ectomy, external-beam radiation therapy, and brachytherapy.

21 melanomas are currently treated with plaque brachytherapy.

22 adiation, including external beam and plaque brachytherapy.

23 y treated by prostatectomy, radiotherapy, or brachytherapy.

24 nd nine (11%) patients underwent concomitant brachytherapy.

25 electron beam techniques and high-dose rate brachytherapy.

26 Palladium-103 plaque brachytherapy.

27 , has been obtained with image-guided breast brachytherapy.

28 Gy, and high- or low-dose rate intracavitary brachytherapy.

29 ontrols treated with surgery plus iodine-125 brachytherapy.

30 herapy are uncommon 5 years after episcleral brachytherapy.

31 d the complexity of performing intravascular brachytherapy.

32 x patients underwent angioplasty followed by brachytherapy.

33 d with uveal melanoma, 311 were treated with brachytherapy.

34 external beam radiation therapy or invasive brachytherapy.

35 reatment with palladium-103 ((103)Pd) plaque brachytherapy.

36 P classification testing after I(125) plaque brachytherapy.

37 lary vasculature changes after I(125) plaque brachytherapy.

38 Iodine-125 plaque brachytherapy.

39 ceived APBI using interstitial multicatheter brachytherapy.

40 to predict vision loss following episcleral brachytherapy.

41 for patients being evaluated for episcleral brachytherapy.

42 east irradiation or APBI using multicatheter brachytherapy.

43 SM and ACM during the first decade following brachytherapy.

44 ration biopsy of choroidal tumors undergoing brachytherapy.

45 atherectomy (0.96 [0.53-1.7]), and vascular brachytherapy (0.60 [0.35-1.0]).

46 ty-adjusted life-years [QALYs]), followed by brachytherapy (10.57 QALYs), IMRT (10.51 QALYs), and rad

47 ), chemotherapy combined with teletherapy or brachytherapy (14%), enucleation (3%), or observation (2

48 radiotherapy (13.9 [95% CI, 6.7-21.2]), and brachytherapy (17.1 [95% CI, 7.8-26.6]).

49 m radiotherapy (11.7 [95% CI, 8.7-14.8]) and brachytherapy (20.5 [95% CI, 15.1-25.9]); and worsened b

50 with re-DES (58.1%), 132 underwent vascular brachytherapy (23.4%), and 104 were treated with convent

51 nts, -19.2% (-28.2 to -10.4) versus vascular brachytherapy, -23.4% (-36.2 to -10.8) versus bare metal

52 mastectomy was higher in women treated with brachytherapy (3.95%; 95% CI, 3.19%-4.88%) vs WBI (2.18%

53 vant pelvic radiotherapy (34.3% v 31.3%) and brachytherapy (33.6% v 31.0%; P < .05).

54 Of women treated with brachytherapy, 34.3% had a complication compared with 27

55 starting with external radiotherapy (63%) or brachytherapy (37%).

56 ectomy, 11.6% external-beam radiation, 13.3% brachytherapy, 4.0% cryoablation, and 14.4% androgen dep

57 Low-dose iodine-125 plaque brachytherapy (67.5-81 Gy at tumor apex) provides safe a

58 patients completed external radiation (99%), brachytherapy (75%), radiosensitizing therapy (98%), and

59 with teletherapy (31%), chemotherapy (18%), brachytherapy (9%), chemotherapy combined with telethera

60 external beam radiotherapy (21.8%), and 109 brachytherapy (9.6%).

61 When analyzed strictly as brachytherapy, (90)Y radioembolization planned by predic

62 characteristics, 35.2% of women treated with brachytherapy (95% CI, 28.6 to 41.9) had a complication

63 s the feasibility of tumor-specific prostate brachytherapy achievable with Yb-169 and actively target

64 Therefore, adjuvant APBI using multicatheter brachytherapy after breast-conserving surgery in patient

65 In recent years, use of breast brachytherapy after lumpectomy for early breast cancer h

66 One underwent FNAB only but did not undergo brachytherapy afterward.

67 High dose-rate (HDR) brachytherapy allows for control of the depth of radiati

68 brachytherapy followed by EBRT (n = 288) or brachytherapy alone (n = 280).

69 state-specific antigen, 10 to 20 ng/mL), LDR brachytherapy alone may be offered as monotherapy.

70 cancer (PC) -specific mortality (PCSM) after brachytherapy alone or in conjunction with androgen supp

71 stimate the risk of PCSM in men treated with brachytherapy alone or with supplemental AST, EBRT, or b

72 EBRT but not either supplement compared with brachytherapy alone was associated with a decreased risk

73 When compared with brachytherapy alone, a significant decrease in the risk

74 is review addresses the mechanisms that make brachytherapy an effective tool for restenosis and its a

75 sel failure was 21.6% (27/125) with vascular brachytherapy and 12.4% (32/259) with the sirolimus-elut

76 here have been sharp increases in the use of brachytherapy and androgen deprivation monotherapy, from

77 0.14 to 0.73; P = .006) in men treated with brachytherapy and both AST and EBRT as compared with nei

78 For the iodine-125 brachytherapy and endoresection groups, respectively, th

79 response parameters based on experience with brachytherapy and external-beam radiation therapy to pro

80 Rates of brachytherapy and hormonal therapy use, in particular, h

81 ique costs of external-beam radiotherapy and brachytherapy and included a specific valuation of women

82 y, endoscopic ultrasound-guided interstitial brachytherapy and injection of therapeutic agents into t

83 h choroidal melanoma treated with iodine-125 brachytherapy and intraoperative FNAB from January 2005

84 tive benefit of alternative forms of RT (ie, brachytherapy and protons); target localization; the use

85 been reported in bare-metal stents (BMS) and brachytherapy and recently in drug-eluting stents.

86 Lesion length was similar between vascular brachytherapy and sirolimus-eluting stent patients (mean

87 2000, 638 of the 650 patients randomized to brachytherapy and so treated had been followed up for 1

88 s review focuses on the delivery devices for brachytherapy and their application in prostate, breast,

89 lanoma that cannot be handled with ruthenium-brachytherapy and therefore is a challenge for ophthalmo

90 n of radiation therapy techniques related to brachytherapy and three-dimensional conformal radiation

91 dal tumor, which was treated with iodine-125 brachytherapy and underwent intraoperative fine-needle a

92 d deep-tissue and bone complications between brachytherapy and WBI at 1 year of follow-up.

93 -up was 14.1% for re-DES, 17.5% for vascular brachytherapy, and 18.0% for conventional balloon angiop

94 All patients were treated with I-125 brachytherapy, and 2 received associated transpupillary

95 including stenting, laser photocoagulation, brachytherapy, and chemotherapy used singly or in combin

96 omen were treated with external irradiation, brachytherapy, and concurrent chemotherapy from January

97 l prostatectomy, external beam radiotherapy, brachytherapy, and cryotherapy will be reviewed.

98 s such as photodynamic therapy, intraluminal brachytherapy, and high-intensity ultrasound therapy may

99 with external irradiation and intracavitary brachytherapy, and most received concurrent weekly cispl

100 therapy, sublobar resection, intraoperative brachytherapy, and radiofrequency ablation.

101 atherectomy, drug-coated balloons, vascular brachytherapy, and surgical revascularization.

102 y, being used in external-beam radiotherapy, brachytherapy, and targeted radionuclide therapy.

103 l recurrence, including proton beam therapy, brachytherapy, and transpupillary thermotherapy used for

104 re enucleated during the first 5 years after brachytherapy, and treatment failure was reported for 57

105 of sources, including x-rays, beam therapy, brachytherapy, and various injected radionuclides.

106 Local recurrences following brachytherapy are uncommon 5 years after episcleral brac

107 en patients died during follow-up: 11 in the brachytherapy arm vs 3 in the endoresection arm (20.4% a

108 criteria after external-beam radiotherapy or brachytherapy as primary treatment.

109 As interventional radiotherapy (brachytherapy) as yet lacks any such long-term studies,

110 tended tumor retention allowed for effective brachytherapy, as indicated by extended survival time (>

111 therapy were imaged again after I-125 plaque brachytherapy at 6 and 18 months.

112 adenocarcinoma of the prostate treated with brachytherapy at the Prostate Cancer Foundation of Chica

113 He has decided against prostatectomy and brachytherapy because of strong personal preference.

114 with iodine 125 or ruthenium 106 episcleral brachytherapy between January 1, 2004, and December 30,

115 n of androgen-deprivation therapy (ADT) or a brachytherapy boost (BT) to external beam radiotherapy (

116 iving EBRT and androgen-deprivation therapy, brachytherapy boost (LDR or HDR) should be offered to el

117 ith or without androgen-deprivation therapy, brachytherapy boost (LDR or high-dose rate [HDR]) should

118 l conformal radiation therapy [3-D CRT]), or brachytherapy (BT) were recontacted at a median of 6.2 y

119 external beam radiation therapy (EBRT); (2) brachytherapy (BT); (3) both EBRT and BT.

120 However, brachytherapy can only be used in localized and relative

121 or retinoblastoma were developed; and plaque brachytherapy, chemoreduction, intra-arterial chemothera

122 median survival, was performed with previous brachytherapy clinical studies, which showed a proportio

123 The main advantage of brachytherapy compared with external beam radiation (EBR

124 e significantly higher among women receiving brachytherapy compared with those receiving WBI.

125 der women with breast cancer, treatment with brachytherapy compared with WBI was associated worse wit

126 Particle teletherapy and brachytherapy continue to show promise in some clinical

127 egression response after iodine 125 (I(125)) brachytherapy correlates with class 2 GEP status.

128 No randomized trial evaluated brachytherapy, cryotherapy, robotic radical prostatectom

129 Treatment with plaque brachytherapy demonstrates excellent outcomes in a commu

130 Brachytherapy devices have yielded promising results in

131 Brachytherapy did not reduce LR after SR.

132 f 8 acral CTCL lesions received low-dose HDR brachytherapy during a 3-year period.

133 However, prostatectomy, radiotherapy, and brachytherapy each can lead to distinct adverse effects.

134 omy with a single 24-gray dose of epimacular brachytherapy (EMB), delivered with an intraocular, hand

135 External beam and brachytherapy emissions are composed of photons, whereas

136 Brachytherapy enables the delivery of a high radiation d

137 tients treated with repeat episcleral plaque brachytherapy (EPBT) for locally recurrent posterior uve

138 Recently, electronic surface brachytherapy (ESB) has been described as a noninvasive

139 a higher prevalence of prior stent/vascular brachytherapy failure than did the rest of the populatio

140 The brachytherapy film used for treatment was the RIC Confor

141 idal melanoma, intraoperative FNAB, and post-brachytherapy follow-up of 1 to 6 years (mean, 2.7 +/- 1

142 e randomly assigned to either vaginal radium brachytherapy followed by EBRT (n = 288) or brachytherap

143 study investigated the role of low-dose HDR brachytherapy for acral CTCL lesions.

144 of scaling up external-beam radiotherapy and brachytherapy for cervical cancer in upper-middle-income

145 eluting stent implantation to intravascular brachytherapy for in-stent stenosis of bare metal stents

146 The role of intravascular brachytherapy for in-stent stenosis of drug eluting sten

147 To evaluate low- vs high-dose plaque brachytherapy for juxtapapillary choroidal melanoma.

148 GFR) ((177)Lu-T-AuNP) as a novel neoadjuvant brachytherapy for LABC.

149 update the Cancer Care Ontario guideline on brachytherapy for patients with prostate cancer to accou

150 A total of 375 eyes treated with episcleral brachytherapy for posterior uveal melanoma from January

151 ter prostatectomy, external radiotherapy, or brachytherapy for prostate cancer.

152 ter prostatectomy, external radiotherapy, or brachytherapy for prostate cancer.

153 To date, the literature on renal artery brachytherapy for restenosis consists of several singula

154 angiographic outcomes compared with vascular brachytherapy for the treatment of restenosis within a b

155 Vision loss following episcleral brachytherapy for uveal melanoma is difficult to predict

156 6 to 2011; all patients who underwent plaque brachytherapy for uveal melanoma were included.

157 y-based institutional experience with plaque brachytherapy for uveal melanomas with a focus on local

158 olving partial breast irradiation, including brachytherapy, for breast cancer; and currently accruing

159 melanoma who were treated with I(125) plaque brachytherapy from January 2007 through January 2011 wit

160 e review of patients who underwent MammoSite brachytherapy from October 2003 to March 2007.

161 -PMB was carried out transperineally using a brachytherapy grid under TRUS guidance.

162 segment was 29.5% (31/105) for the vascular brachytherapy group and 19.8% (45/227) for the sirolimus

163 s required in 19.2% (24/125) of the vascular brachytherapy group and 8.5% (22/259) of the sirolimus-e

164 success was 99.2% (124/125) in the vascular brachytherapy group and 97.3% (250/257) in the sirolimus

165 Patients in the brachytherapy group reported having long-lasting urinary

166 as observed in 11 patients in the iodine-125 brachytherapy group vs only 1 patient in the endoresecti

167 Compared with the vascular brachytherapy group, minimal lumen diameter was larger i

168 Prostate brachytherapy has become a common treatment modality for

169 Vascular brachytherapy has demonstrated its efficacy in limiting

170 Brachytherapy has disseminated into clinical practice as

171 These findings show that this nanoseed-based brachytherapy has the potential to provide a theranostic

172 These injectable brachytherapy hydrogels were used to treat two aggressiv

173 ranial ependymomas treated with interstitial brachytherapy (IBT).

174 artery chemotherapy in 5 (16%) eyes, plaque brachytherapy in 5 (16%), transpupillary thermotherapy (

175 e potential advantages for the role of focal brachytherapy in early PCa.

176 external beam radiation therapy (EBRT) with brachytherapy in men with prostate cancer.

177 as a relatively infrequent event after I-125 brachytherapy in our series.

178 e of PTEN, indicating clinical potential for brachytherapy in patients with intermediate and high ris

179 , and the management of recurrence following brachytherapy in patients with posterior uveal melanoma,

180 acteristics of treatment failure after I-125 brachytherapy in patients with uveal melanoma treated an

181 e of an intraoperative high-dose rate of 32P brachytherapy in selected cases of recalcitrant diffuse

182 troversy regarding the role of intravascular brachytherapy in the setting of growing use of drug elut

183 One patient was treated with brachytherapy in two SVGs but had a recurrence four mont

184 hip exists following treatment with prostate brachytherapy; in other words, dosimetry matters and poo

185 ris melanoma regression after (103)Pd plaque brachytherapy included decreased intrinsic tumor vascula

186 The modern technique of prostate brachytherapy includes three components, (1) treatment p

187 erformed: men were treated at diagnosis with brachytherapy, intensity-modulated radiation therapy (IM

188 Treatment (brachytherapy, intensity-modulated radiation therapy, or

189 y include high-intensity focused ultrasound, brachytherapy, interstitial laser thermotherapy, stereot

190 y available methods of APBI are interstitial brachytherapy, intracavitary brachytherapy, intraoperati

191 re interstitial brachytherapy, intracavitary brachytherapy, intraoperative radiotherapy, and three-di

192 Brachytherapy is a common clinical technique involving i

193 Brachytherapy is a method for delivering partial-breast

194 Brachytherapy is a radiation treatment that uses an impl

195 ancer and < 50% myometrial invasion, vaginal brachytherapy is as effective as pelvic radiation therap

196 The utility of intravascular brachytherapy is being rethought in relation to its use

197 Brachytherapy is commonly used among Medicare beneficiar

198 in-stent stenosis, the role of intravascular brachytherapy is decreasing primarily due to the simplic

199 Brachytherapy is described as the short distance treatme

200 needle aspiration biopsy immediately before brachytherapy is excellent for obtaining tumor aspirate

201 ries and case reports demonstrate that renal brachytherapy is feasible and safe.

202 Intracoronary brachytherapy is the only adjuvant therapy that has been

203 Although vascular brachytherapy is the only approved therapy for restenosi

204 Intratumoral radiation therapy - 'brachytherapy' - is a highly effective treatment for sol

205 apy, especially interventional radiotherapy (brachytherapy), is a technically feasible treatment tech

206 re or choose active treatment, low-dose rate brachytherapy (LDR) alone, EBRT alone, and/or radical pr

207 Conservative treatment options include brachytherapy, local resection and/or cryotherapy in sel

208 Adjuvant brachytherapy may reduce LR This multicenter randomized

209 Epimacular brachytherapy may reduce the need for frequent anti-VEGF

210 as combining interstitial and intracavitary brachytherapy, may be more appropriate for improving the

211 After brachytherapy, mean tumor thickness decreased to 0.9+/-0

212 Vascular brachytherapy (n = 125) or the sirolimus-eluting stent (

213 = 4), followed by cryotherapy (n = 3) and/or brachytherapy (n = 3).

214 on therapy (EBRT; n = 261), or low-dose-rate brachytherapy (n = 87) for men with favorable-risk disea

215 For the pancreatic tumors, ELP brachytherapy (n=6) induced significant growth inhibitio

216 ies under investigation include interstitial brachytherapy, new chemotherapeutic agents that cross th

217 e isotope options for patients receiving LDR brachytherapy; no recommendation can be made for or agai

218 mising for their application for neoadjuvant brachytherapy of LABC.

219 xudative retinal detachment resolution after brachytherapy of posterior uveal melanoma.

220 A total of 107 patients underwent plaque brachytherapy, of which 88 had follow-up data available.

221 mour bed, and APBI was delivered as 34 Gy of brachytherapy or 38.5 Gy of external bream radiation the

222 gest differences in efficacy for one form of brachytherapy or another.

223 radical prostatectomy, and in 5-9% following brachytherapy or cryotherapy after prostate cancer.

224 ity-of-life domains among patients receiving brachytherapy or radiotherapy.

225 procedure rates declined with later year of brachytherapy (OR, 0.93/yr; P < .01).

226 privation (OR, 1.31; P < .01), later year of brachytherapy (OR, 1.03/yr; P = .02), higher Charlson co

227 l prostatectomy, external beam radiotherapy, brachytherapy, or active surveillance.

228 ters before and after radical prostatectomy, brachytherapy, or external-beam radiotherapy.

229 ore appropriate for improving the quality of brachytherapy plans associated with inadequate target co

230 e whether IPSA could improve cervical cancer brachytherapy plans giving D90 < 6 Gy (with 7 Gy per fra

231 annealing (IPSA) can improve the quality of brachytherapy plans, and we wanted to examine whether IP

232 dollars); of brachytherapy plus IMRT versus brachytherapy plus 3D-CRT was $10,789; of MIRP versus op

233 sus 3D-CRT was $10,986 (in 2008 dollars); of brachytherapy plus IMRT versus brachytherapy plus 3D-CRT

234 ng of $282 million for IMRT, $59 million for brachytherapy plus IMRT, and $4 million for MIRP, compar

235 roups; however, patients undergoing vascular brachytherapy presented with more complex lesions and a

236 Epimacular brachytherapy produces stable visual acuity in most part

237 The precise and targeted nature of brachytherapy provides a number of key benefits for the

238 s case series demonstrates that low-dose HDR brachytherapy provides excellent palliation for local co

239 nt incorporation procedure, palladium-103, a brachytherapy radioisotope in clinical practice, was coa

240 iotherapy, intensity-modulated radiotherapy, brachytherapy, radiosurgery, and photodynamic therapy fo

241 The most common long-term brachytherapy-related complication was radiation maculop

242 The most common long-term brachytherapy-related complications were radiation macul

243 n men who opted for radical prostatectomy or brachytherapy, reported close attention to current PSA,

244 een treated by external-beam radiotherapy or brachytherapy, respectively.

245 Brachytherapy results in the most irritative urinary sym

246 l treatment failure in this series, and post-brachytherapy retinal detachment occurred in 3 eyes.

247 A few reports have suggested stereotactic brachytherapy (SBT) with implantation of iodine-125 ((12

248 hly conformal radiotherapy or high-dose rate brachytherapy.See related article by Torok et al., p.

249 ation is designed to perform fully automated brachytherapy seed placement within a closed MR imager.

250 raphy is mainly used for biopsy guidance and brachytherapy seed placement.

251 latters containing ~ 250 mCi each of (137)Cs brachytherapy seeds are mounted above and below the "hot

252 Making use of discarded (137)Cs brachytherapy seeds, the VADER can provide varying low d

253 Electronic surface brachytherapy should be used with caution, particularly

254 nter randomized trial compares SR to SR with brachytherapy (SRB).

255 .7% v 81.7%; P < .001) and for men receiving brachytherapy, supplemental IMRT increased significantly

256 iew highlights the rationale and outcomes of brachytherapy techniques.

257 y feasible with both newer external-beam and brachytherapy technology.

258 ation approval and Medicare reimbursement of brachytherapy technology.

259 ne and the other comprised mice treated with brachytherapy that received 1.11 MBq of (1)(7)(7)Lu-DOTA

260 This analysis documents the efficacy of brachytherapy to achieve sustained local tumor control a

261 adjunct to needle biopsy immediately before brachytherapy to minimize these complications and preser

262 iotherapy) plus high-dose-rate intracavitary brachytherapy (to bring the total dose to point A to 80

263 uveal melanoma after primary treatment with brachytherapy, transpupillary thermotherapy, proton beam

264 Brachytherapy treatment was well tolerated, with clinica

265 Recurrent tumors were managed by repeat brachytherapy, TTT, or enucleation.

266 Frequency of brachytherapy use as an alternative to external-beam rad

267 Brachytherapy use was also more likely in women with non

268 Brachytherapy use was more likely in women with lymph no

269 Logistic regression modeled predictors of brachytherapy use.

270 The percent of patients receiving brachytherapy varied substantially across HRRs, ranging

271 ent recurrence rates are high, with vascular brachytherapy (VBT) affording the best results.

272 oduction of two major advances, the vascular brachytherapy (VBT) and the drug-eluting stents (DES).

273 T (PORTEC-1; n = 714) or EBRT versus vaginal brachytherapy (VBT; PORTEC-2; n = 427).

274 laims codes identified patients treated with brachytherapy versus external-beam radiation after BCS f

275 r lumpectomy 6952 patients were treated with brachytherapy vs 85,783 with WBI.

276 CI, 85.94%-89.18%) in patients treated with brachytherapy vs 87.04% (95% CI, 86.69%-87.39%) in patie

277 ostatectomy, external beam radiotherapy, and brachytherapy vs active surveillance.

278 Recurrence-free survival 24 months after brachytherapy was 75% (95% CI, 19-89.1).

279 I(125) brachytherapy was administered via episcleral plaque acc

280 Brachytherapy was associated with a 16.9% higher rate of

281 Brachytherapy was associated with more frequent infectio

282 Low-dose-rate brachytherapy was associated with worse urinary irritati

283 Morbidity after prostate brachytherapy was common, though invasive procedures wer

284 cleral FNAB at the time of iodine-125 plaque brachytherapy was not associated with endophthalmitis, o

285 ongoing questions regarding efficacy, breast brachytherapy was rapidly incorporated into the care of

286 Brachytherapy was the most effective and least expensive

287 rom 1995 to 2016 and treated with episcleral brachytherapy were included.

288 ients had a 20% restenosis rate 1 year after brachytherapy, when Doppler ultrasound was used for foll

289 LDR mimicking brachytherapy, which is used successfully in the clinic,

290 Adult UM patients treated with I(125) plaque brachytherapy who had concurrent tumor biopsy at the tim

291 gests that the need to perform intravascular brachytherapy will be in fewer than one in 20 patients.

292 and suggests that the need for intravascular brachytherapy will significantly decrease.

293 There were 5,621 men who had brachytherapy with at least 2 years of follow-up.

294 eatment included external beam radiation and brachytherapy with concurrent cisplatin chemotherapy.

295 Palladium 103 plaque brachytherapy with or without extraocular muscle surgery

296 eceived surgery (26%), external RT (38%), or brachytherapy with or without RT (36%).

297 r the feasibility of tumor-specific prostate brachytherapy with Yb-169 and gGNRs.

298 re relatively infrequent events after I(125) brachytherapy within the COMS.

299 Study for tumors of the same size treated by brachytherapy without biopsy.

300 Analyses were adjusted for age at brachytherapy, year of treatment, and known PC prognosti